Molinalogo

Measure

2021

2022

Goal

Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)

59.25%

51.50%

64.52%

Annual Dental Visits (ADV) Total

48.14%

49.13%

53.67%

Antidepressant Medication Management (AMM) Effective Continuation Phase Treatment

58.89%

61.18%

46.09%

Appropriate Testing for Pharyngitis (CWP)

75.29%

74.02%

74.02%

Appropriate Treatment for Upper Respiratory Infection (URI)

74.74%

73.88%

92.46%

Asthma Medication Ratio (AMR) Total

62.89%

64.75%

68.21%

Avoidance of Antibiotic Treatment for Acute Bronchitis / Bronchiolitis (AAB) Total

55.84%

48.25%

58.74%

Breast Cancer Screening (BCS)

36.36%

33.33%

53.96%

Cervical Cancer Screening (CCS)

47.93%

52.31%

60.83%

Childhood Immunization Status (CIS) Combination #10

17.27%

20.68%

39.42%

Chlamydia Screening in Women (CHL) Total

53.13%

52.19%

60.24%

Comprehensive Diabetes Care (CDC) BP Control < 140/90

51.82%

53.77%

65.21%

Comprehensive Diabetes Care (CDC) HbA1c Control < 8.0%

36.25%

30.17%

52.80%

Comprehensive Diabetes Care (CDC) Eye Exam

49.15%

53.28%

54.74%

Controlling High Blood Pressure (CBP)

47.20%

50.12%

63.50%

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

71.19%

70.60%

81.21%

Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA) 7-Day Follow-Up Total

2.73%

3.77%

16.16%

Follow-Up After Emergency Department Visit for Mental Illness (FUM) 7-Day Follow-Up Total

18.75%

31.70%

45.35%

Follow-Up After Hospitalization for Mental Illness (FUH) 7-Day Follow-Up Total

29.44%

30.63%

42.75%

Follow-Up After High-Intensity Care for Substance Use Disorder (FUI) 7-Day Follow-Up Total

21.05%

13.33%

37.86%

Follow-Up for Children Prescribed ADHD Medication (ADD)Continuation and Maintenance Phase

60.66%

38.46%

55.40%

Immunizations for Adolescents (IMA) Combination #2

10.22%

10.95%

39.16%

Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) Engagement of AOD Treatment Total

7.05%

6.82%

16.57%

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) Total

16.49%

22.24%

39.29%

Pharmacotherapy for Opioid Use Disorder (POD) Total

60.66%

49.59%

33.15%

Pharmacotherapy Management of COPD Exacerbation (PCE) Systemic Corticosteroids

54.39%

60.48%

74.76%

Pharmacotherapy Management of COPD Exacerbation (PCE) Bronchodilator

80.70%

80.65%

87.83%

Plan All-Cause Readmissions (PCR) Observed-to-Expected Ratio 18-64 Years

118.15%

104.10%

≤ 94.44%

Prenatal and Postpartum Care (PPC) Timeliness of Prenatal Care

95.38%

91.24%

87.83%

Prenatal and Postpartum Care (PPC) Postpartum Care

66.42%

63.50%

80.00%

Prenatal Immunization Status (PRS) Combination Rate

NR

8.16%

27.32%

Risk of Continued Opioid Use (COU) 31-Day Total

4.43%

3.42%

≤ 2.35%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Received Statin Therapy Total

78.95%

76.38%

82.29%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Statin Adherence 80% Total

86.67%

85.57%

73.75%

Statin Therapy for Patients with Diabetes (SPD) Received Statin Therapy

52.14%

51.36%

68.32%

Statin Therapy for Patients with Diabetes (SPD) Statin Adherence 80%

77.05%

77.06%

70.00%

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) Total

57.02%

59.43%

65.63%

Use of Imaging Studies for Low Back Pain (LBP)

71.96%

67.49%

76.82%

Use of Opioids at High Dosage (HDO)

4.76%

3.42%

≤ 2.65%

Use of Opioids from Multiple Providers (UOP) Multiple Prescribers and Multiple Pharmacies

2.80%

0.80%

≤ 0.90%

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) BMI Percentile

49.15%

54.26%

82.73%